State Street Corp Has $5.36 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

State Street Corp increased its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 7.4% in the third quarter, HoldingsChannel reports. The firm owned 772,825 shares of the company’s stock after buying an additional 52,966 shares during the period. State Street Corp’s holdings in Zevra Therapeutics were worth $5,363,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the period. Stonepine Capital Management LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth approximately $4,858,000. Vestal Point Capital LP acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $3,644,000. Retirement Planning Co of New England Inc. grew its holdings in Zevra Therapeutics by 6.5% in the 2nd quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after buying an additional 28,107 shares in the last quarter. Finally, Mystic Asset Management Inc. increased its position in Zevra Therapeutics by 11.9% during the 2nd quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock worth $1,460,000 after buying an additional 31,650 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $8.39 on Monday. The firm has a market cap of $447.82 million, a PE ratio of -4.26 and a beta of 1.97. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The firm’s fifty day moving average is $8.74 and its 200-day moving average is $7.39. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the company posted ($0.40) EPS. Sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on ZVRA shares. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. Guggenheim began coverage on Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $21.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.